Dr. Roham Zamanian discusses pulmonary complications of scleroderma. As a leading team member of the Stanford Pulmonary Hypertension (PH) Program, Dr. Zamanian provides insights on the comprehensive diagnostic and therapeutic services available to patients with all forms of pulmonary hypertension.
Fifteen years ago, pulmonary hypertension was considered to be a uniformly progressive and fatal disease. While exciting new treatments have been developed since then, patients with pulmonary hypertension face a truly life-threatening illness. Dr. Zamanian educates viewers on PH and the research being done to develop new treatments and prolong the life of patients.
Since releasing this video, we've updated our contact information.
www.srfcure.org | 415.834.9444
Scleroderma Research Foundation
220 Montgomery St. Suite 484
San Francisco, CA 94104
